Andere talen SELLAS Life Sciences Group, Inc.

Aandelen

SLS

US81642T2096

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 30-04-2024			Voorbeurs 14:58:05
1,24 ^USD	+2,48%		1,635	+31,85%

29/04	SELLAS Life Sciences Group, Inc. Kondigt een positieve aanbeveling aan van de onafhankelijke commissie voor gegevenscontrole na voltooiing van de registratie in de REGAL fase 3 studie	CI
28/03	SELLAS Life Sciences Group, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level	14:35
SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study	29/04
SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study	29/04
North American Morning Briefing : Powell Awaited -2-	03/04
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update	28/03
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study	26/03
SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML	26/03
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET	19/03
Sector Update: Health Care Stocks Ease Late Afternoon	15/03
Top Midday Decliners	15/03
Sector Update: Health Care Stocks Softer Friday Afternoon	15/03
Sellas Life Sciences Launches $20 Million Direct Offering, Private Placement -- Shares Fall	15/03
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	15/03
SELLAS Life Sciences Group, Inc. announced a financing transaction	15/03
SELLAS Life Sciences : Material Event - Form 8-K	11/03
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships	08/03
SELLAS Life Sciences Group, Inc. Announces Executive Changes	08/03
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference	01/03
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time	29/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen SELLAS Life Sciences Group, Inc.

Aandelen

SLS

US81642T2096

Andere talen

Filters